R S Fontana1. 1. Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. robfontana@aol.com
Abstract
BACKGROUND: The Mayo Lung Project (MLP) was a randomized, controlled, clinical trial designed to determine whether intensive radiologic and cytologic screening for lung carcinoma could reduce lung carcinoma mortality significantly. METHODS: Half the MLP population was encouraged (and reminded) to undergo free chest X-rays and free sputum cytology tests every 4 months for 6 years, whereas the other half of the population was advised to undergo the 2 tests yearly. RESULTS:Lung carcinoma incidence rate, resectability, and survivorship were greater in the intensively screened group compared with the control group, but there was no significant difference in the lung carcinoma mortality rate between the two groups. CONCLUSIONS: The intensive screening program cannot be recommended as a public health measure because it did not appear to result in decreased lung carcinoma mortality, even though it did yield an increased rate of incidence of apparently indolent tumors.
RCT Entities:
BACKGROUND: The Mayo Lung Project (MLP) was a randomized, controlled, clinical trial designed to determine whether intensive radiologic and cytologic screening for lung carcinoma could reduce lung carcinoma mortality significantly. METHODS: Half the MLP population was encouraged (and reminded) to undergo free chest X-rays and free sputum cytology tests every 4 months for 6 years, whereas the other half of the population was advised to undergo the 2 tests yearly. RESULTS:Lung carcinoma incidence rate, resectability, and survivorship were greater in the intensively screened group compared with the control group, but there was no significant difference in the lung carcinoma mortality rate between the two groups. CONCLUSIONS: The intensive screening program cannot be recommended as a public health measure because it did not appear to result in decreased lung carcinoma mortality, even though it did yield an increased rate of incidence of apparently indolent tumors.
Authors: Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum Journal: N Engl J Med Date: 2013-05-23 Impact factor: 91.245
Authors: Dana Li; Bolette Mikela Vilmun; Jonathan Frederik Carlsen; Elisabeth Albrecht-Beste; Carsten Ammitzbøl Lauridsen; Michael Bachmann Nielsen; Kristoffer Lindskov Hansen Journal: Diagnostics (Basel) Date: 2019-11-29
Authors: Luis E Raez; Amanda Nogueira; Edgardo S Santos; Ricardo Sales Dos Santos; Juliana Franceschini; David Arias Ron; Mark Block; Nise Yamaguchi; Christian Rolfo Journal: J Glob Oncol Date: 2018-09